AtriCure falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #66. Since the beginning of the year, the industry has moved +9.9%. AnaptysBio ...

Discovering AnaptysBio: A Closer Look AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in ...

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 update. The firm is “encouraged” by the ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB ... “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this ...

AnaptysBio’s Phase IIb trial of its rheumatoid ... supported by objective translational data and surpass our target product profile in the $20bn US RA market." Faga added that in Q2 2025 ...

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in ...

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...